Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio predict the prognosis in...

Area of Science:

• Cardiovascular Medicine
• Metabolic Syndrome
• Vascular Surgery

Background:

• The triglyceride-glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio are established indicators of insulin resistance.
• These metabolic markers have demonstrated utility in predicting various cardiovascular diseases.
• The prognostic value of the TG/HDL-c ratio in type B aortic dissection (TBAD) patients undergoing thoracic endovascular aortic repair (TEVAR) remains underexplored.

Purpose of the Study:

• To investigate the association between the TG/HDL-c ratio and clinical outcomes in patients with TBAD treated with TEVAR.
• To determine if baseline TG/HDL-c ratio is an independent predictor of mortality and other adverse events following TEVAR for TBAD.

Main Methods:

• A cohort of 935 patients who underwent TEVAR for TBAD was analyzed.
• The study assessed 30-day and 1-year aortic-related adverse events (ARAEs), all-cause mortality, and major adverse cardiovascular and cerebrovascular events (MACCEs).
• Statistical analysis, including multivariable adjustment, was performed to identify independent predictors of mortality.

Main Results:

• After adjusting for confounders, a continuous TG/HDL-c ratio was independently associated with 1-year all-cause mortality (HR=1.07; P=0.041).
• Both high (Quintile 5: ≥4.11) and low (Quintile 1: <1.44) TG/HDL-c ratios were identified as independent risk factors for 1-year all-cause mortality (HR=4.84 and HR=4.67, respectively; P<0.007).
• Mean follow-up was 2.8 years.

Conclusions:

• An elevated baseline TG/HDL-c ratio (≥4.11) is significantly associated with increased 1-year all-cause mortality in TBAD patients undergoing TEVAR.
• Conversely, a low TG/HDL-c ratio (<1.44) also independently predicts higher 1-year all-cause mortality in this patient group.
• Clinicians should consider both high and low TG/HDL-c ratios as important prognostic factors in TBAD patients treated with TEVAR.